INT172874

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.80
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 31
Total Number 33
Disease Relevance 27.46
Pain Relevance 2.07

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Bad) cell proliferation (Bad) cytosol (Bad)
mitochondrion (Bad) cytoplasm (Bad)
Anatomy Link Frequency
neurons 3
Bad (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 24 99.66 Very High Very High Very High
withdrawal 21 99.58 Very High Very High Very High
addiction 19 99.50 Very High Very High Very High
Eae 24 92.36 High High
dexamethasone 8 91.76 High High
Morphine 120 90.84 High High
antagonist 65 87.64 High High
metalloproteinase 5 46.16 Quite Low
cINOD 39 39.76 Quite Low
imagery 101 36.92 Quite Low
Disease Link Frequency Relevance Heat
Apoptosis 1132 99.92 Very High Very High Very High
Death 206 99.92 Very High Very High Very High
Prostate Cancer 671 99.84 Very High Very High Very High
Cancer 892 98.96 Very High Very High Very High
Infection 86 92.24 High High
Colon Cancer 12 91.76 High High
Breast Cancer 30 84.00 Quite High
Stress 91 83.52 Quite High
Targeted Disruption 57 80.64 Quite High
Pancreatic Cancer 170 79.04 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This connection between BAD expression and proliferation provides a possible explanation for an increase in expression of phosphorylated BAD protein in prostate tumors.
Phosphorylation (phosphorylated) of BAD protein associated with prostate cancer
1) Confidence 0.80 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2704953 Disease Relevance 0.76 Pain Relevance 0
Phosphorylated BAD fails to bind Bcl-XL or Bcl-2 proteins, and has been considered an apoptosis sentinel inactivated by anti-apoptotic signals.
Phosphorylation (Phosphorylated) of BAD associated with apoptosis
2) Confidence 0.70 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2704953 Disease Relevance 1.44 Pain Relevance 0.12
In other recent reports, BAD in the phosphorylated form was found to promote assembly of active glucokinase complexes, an initial step of the glycolytic pathway [20], [21].
Phosphorylation (phosphorylated) of BAD
3) Confidence 0.70 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2704953 Disease Relevance 0.71 Pain Relevance 0
When dephosphorylated, BAD promotes apoptosis [11], while in a phosphorylated form it stimulates proliferation and tumor growth in vivo.
Phosphorylation (dephosphorylated) of BAD associated with cancer and apoptosis
4) Confidence 0.70 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2704953 Disease Relevance 0.80 Pain Relevance 0
It seems counterintuitive that prostate cells would dedicate extra resources to maintain BAD phosphorylation instead of eliminating its expression.
Phosphorylation (phosphorylation) of BAD
5) Confidence 0.62 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2704953 Disease Relevance 1.33 Pain Relevance 0.10
Calcitriol treatment also suppresses the phosphorylation of Akt and the expression of Bcl-2 family member BAD 64.
Phosphorylation (phosphorylation) of BAD
6) Confidence 0.61 Published 2010 Journal Journal of Cancer Section Body Doc Link PMC2938072 Disease Relevance 0.83 Pain Relevance 0.05
This combination of proliferative and apoptotic properties creates conditions for prostate cancer cells “addiction” to increased levels of phosphorylated BAD.
Phosphorylation (phosphorylated) of BAD associated with addiction, prostate cancer and apoptosis
7) Confidence 0.54 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2704953 Disease Relevance 1.19 Pain Relevance 0.08
Activation of protein kinases that phosphorylate BAD creates a permissive condition to increased expression of BAD.
Phosphorylation (phosphorylate) of BAD
8) Confidence 0.54 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2704953 Disease Relevance 0.57 Pain Relevance 0
If so, high levels of phosphorylated BAD could be used to identify patients who will benefit from therapy with such inhibitors.
Phosphorylation (phosphorylated) of BAD
9) Confidence 0.54 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2704953 Disease Relevance 0.41 Pain Relevance 0
Thus, kinases that phosphorylate BAD are plausible therapeutic targets; while monitoring BAD phosphorylation could be used to predict tumor response to treatments.



Phosphorylation (phosphorylation) of BAD associated with cancer
10) Confidence 0.54 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2704953 Disease Relevance 1.30 Pain Relevance 0
Future studies in animal models and analysis of clinical trials data with regard to BAD expression/phosphorylation are needed to determine the translational value of extensive efforts spent studying protein kinases that phosphorylate BAD.



Phosphorylation (expression) of BAD
11) Confidence 0.54 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2704953 Disease Relevance 0.37 Pain Relevance 0
Future studies in animal models and analysis of clinical trials data with regard to BAD expression/phosphorylation are needed to determine the translational value of extensive efforts spent studying protein kinases that phosphorylate BAD.



Phosphorylation (phosphorylation) of BAD
12) Confidence 0.54 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2704953 Disease Relevance 0.37 Pain Relevance 0
Thus, kinases that phosphorylate BAD are plausible therapeutic targets; while monitoring BAD phosphorylation could be used to predict tumor response to treatments.



Phosphorylation (phosphorylate) of BAD associated with cancer
13) Confidence 0.54 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2704953 Disease Relevance 1.39 Pain Relevance 0
These results suggest that increased expression of BAD provides a proliferative advantage to prostate tumors, while BAD dephosphorylation increases sensitivity of prostate cancer cells to apoptosis.
Phosphorylation (dephosphorylation) of BAD associated with prostate cancer and apoptosis
14) Confidence 0.54 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2704953 Disease Relevance 1.41 Pain Relevance 0
At the same time, BAD dephosphorylation increases sensitivity of prostate cancer cells to apoptosis.
Phosphorylation (dephosphorylation) of BAD associated with prostate cancer and apoptosis
15) Confidence 0.54 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2704953 Disease Relevance 1.26 Pain Relevance 0.08
Future studies in animal models and analysis of clinical trials data with regard to BAD expression/phosphorylation are needed to determine the translational value of extensive efforts spent studying protein kinases that phosphorylate BAD.



Phosphorylation (phosphorylate) of BAD
16) Confidence 0.54 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2704953 Disease Relevance 0.35 Pain Relevance 0
Upon withdrawal of survival factors BAD becomes dephosphorylated, shifts the balance of pro- and anti-apoptotic Bcl proteins that triggers release of cytochrome c, SMAC and AIF from mitochondria and subsequently leads to apoptosis [12].
Phosphorylation (dephosphorylated) of BAD associated with apoptosis and withdrawal
17) Confidence 0.54 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2704953 Disease Relevance 1.33 Pain Relevance 0.12
Combination of proliferative and apoptotic properties prompts prostate cancer cells to be “addicted” to increased levels of phosphorylated BAD.
Phosphorylation (phosphorylated) of BAD associated with prostate cancer and apoptosis
18) Confidence 0.54 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2704953 Disease Relevance 1.32 Pain Relevance 0
Thus, activation of EGFR, GPCRs or PI3K pathway leads to BAD phosphorylation and inhibition of apoptosis.
Phosphorylation (phosphorylation) of BAD associated with apoptosis
19) Confidence 0.54 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2704953 Disease Relevance 0.98 Pain Relevance 0
Thus, kinases that phosphorylate BAD are plausible therapeutic targets.


Phosphorylation (phosphorylate) of BAD
20) Confidence 0.54 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2704953 Disease Relevance 1.17 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox